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Abstract 
Background: The TOMM20 gene was previously identified as differentially expressed and methylated between 
severely obese subjects with and without metabolic syndrome (MS). Since metabolic complications do not affect all 
obese patients to the same extent, the aim of this study was to identify methylation quantitative trait loci (meQTL) 
potentially associated with MS‑related complications within the TOMM20 locus.
Methods: Methylation profiling, SNP genotyping and meQTL association tests (general linear models) were per‑
formed in a population of 48 severely obese subjects. Genotyping was extended to a larger population of 1720 
severely obese subjects with or without MS, where genotype‑ and diplotype‑based association tests were assessed 
by logistic regression. In silico analyses were performed using TRAP.
Results: Four SNPs were identified as significant meQTLs for the differentially methylated site cg16490124. Indi‑
viduals carrying rare alleles of rs4567344 (A > G) (P = 4.9 × 10−2) and rs11301 (T > C) (P = 5.9 × 10−3) showed 
decreased methylation levels at this site, whereas those carrying rare alleles of rs4551650 (T > C) (P = 3.5 × 10−15) 
and rs17523127 (C > G) (P = 3.5 × 10−15) exhibited a significant increase in methylation. rs4567344 and rs11301 
were associated with increased susceptibility to exhibit high plasma triglycerides (TG ≥ 1.69 mmol/L), while rare 
alleles of rs4551650 and rs17523127 were significantly more represented in the low plasma total‑C group (total‑
C ≤ 6.2 mmol/L). Haplotype reconstruction with the four meQTLs (rs4567344, rs11301, rs4551650, rs17523127) led to 
the identification of ten different diplotypes, with H1/H2 (GCGG/ACGG) exhibiting a nearly absence of methylation 
at cg16490124, and showing the highest risk of elevated plasma TG levels [OR = 2.03 (1.59–3.59)], a novel association 
with elevated LDL‑cholesterol [OR = 1.86 (1.06–3.27)] and the complete inversion of the protective effect on total‑C 
levels [OR = 2.03 (1.59–3.59)], especially in men. In silico analyses revealed that rs17523127 overlapped the CpG site 
cg16490124 and encompassed the core binding sites of the transcription factors Egr 1, 2 and 3, located within the 
TOMM20 promoter region.
Conclusion: This study demonstrates that TOMM20 SNPs associated with MS‑related lipid alterations are meQTLs 
potentially exerting their action through a CpG methylation‑dependent effect. The strength of the diplotype‑based 
associations may denote a novel meQTL additive action and point to this locus as particularly relevant in the inter‑
individual variability observed in the metabolic profiles of obese subjects.
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Background
Obesity and obesity-related pathologies are major health 
problems worldwide and their prevalence keeps increas-
ing, reaching epidemic proportions [1]. One of the main 
consequences of obesity is the development of the meta-
bolic syndrome (MS), a cluster of metabolic disturbances, 
characterized by elevated waist circumference and 
plasma triglyceride (TG) levels, reduced HDL-cholesterol 
(HDL-C) levels, hyperglycemia and hypertension [2], 
which often progress to overt diabetes and cardiovascu-
lar diseases [3]. Among the main causes leading to the 
development of MS-related complications, the distribu-
tion of adipose tissue is at the foreground, with visceral 
adipose tissue (VAT) being considered as a key factor 
in the development of MS [4]. Concretely, excess VAT 
accumulation and dysfunction have been associated to 
the development of metabolic disturbances, in particular 
those related to lipid, glucose and amino acid metabolism 
[5, 6]. In this sense, an appropriate mitochondrial func-
tion is critical for lipid turnover in VAT [7] and hence 
adipocyte mitochondria have gained a broad interest for 
understanding the role of VAT in the development of 
MS-related complications. Importantly, adipose mito-
chondrial dysfunction has been found in severely obese 
patients, as well as in animal models of obesity and type 2 
diabetes [8, 9]. These mitochondrial alterations have been 
linked with changes in protein levels closely related to 
mitochondrial biogenesis, oxidative capacity or protein 
import machinery [10]. On the other hand, the fact that 
a large proportion of obese individuals remain healthy 
suggests that genetic or epigenetic factors would be play-
ing a key role in the pathogenesis of MS. To date, genetic 
approaches have identified a significant number of loci 
associated with MS, as recently reviewed [11]. Likewise, 
epigenetic studies have also provided potential mecha-
nisms by which genotype and phenotype associations 
could be linked [12, 13]. From an integrative perspec-
tive, DNA methylation levels in so-called CpG (cyto-
sine-phosphate-guanine) dinucleotides have been found 
to be partially dependent on the genetic sequence, and 
defined as methylation quantitative trait loci (meQTL) 
[14]. Previously, although not included in the final report, 
we identified TOMM20 (translocase of outer mitochon-
drial membrane 20 homolog), a gene coding for a central 
component of the receptor complex involved in protein 
recognition and translocation to the mitochondria, as 
significantly overexpressed in severely obese men with 
vs. without MS [15]. Further studies also identified a 
CpG site located within the promoter region of this gene 
(an intergenic region shared with the SNORA14B locus) 
as significantly overmethylated in obese men with vs. 
without MS [13]. A recent GWAS has also found a SNP 
nearby the TOMM20 promoter region as significantly 
associated with total-cholesterol (total-C) and LDL-cho-
lesterol (LDL-C), which further suggests an important 
role of TOMM20 in lipid metabolism [16]. Thus, to shed 
light on the mechanisms by which genetic variants may 
impact CpG methylation and how this interplay is poten-
tially further reflected at the phenotype level, herein we 
integrated genetic and epigenetic approaches by identify-
ing meQTLs located within the TOMM20 locus for fur-
ther association testing with MS-related complications.
Methods
Study population
The study population included 1720 patients (537 men 
and 1183 women) selected on the presence of severe 
obesity (BMI >35  kg/m2), who underwent biliopancre-
atic diversion with duodenal switch at the Quebec Heart 
and Lung Institute (Quebec City, Quebec, Canada). The 
surgical protocol and the standardized procedures to 
measure anthropometric and metabolic parameters are 
described elsewhere [17, 18]. Briefly, fasting plasma glu-
cose levels were measured enzymatically according to the 
method of Richterich [19]. Total-C and TG levels were 
measured in plasma using enzymatic assays on a Techni-
con RA-500 automated analyzer (Bayer, Tarrytown, NY). 
Plasma HDL-C was measured in the supernatant after 
precipitation of LDL-C. Plasma LDL-C was estimated 
with the Friedewald equation [20]. The presence of MS 
was determined using the National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP-ATPIII) 
guidelines when an individual fulfilled three or more 
criteria [2]. All procedures were in accordance with the 
standards of the Laval University ethics committee and 
with the 1964 Helsinki declaration. Written informed 
consent was obtained from all individual participants 
included in the study.
CpG methylation analysis
CpG methylation analysis was conducted in VAT samples 
of 48 severely obese (BMI >40 kg/m2) subjects (31 men 
and 17 women) selected from the study population and 
fulfilling at least three NCEP-ATPIII criteria. Metabolic 
status was taken into account to include similar propor-
tions of individuals with and without MS (MS+ and 
MS−, respectively), according to NCEP-ATPIII guide-
lines [2]. As previously described [13], genomic DNA was 
extracted from 200 mg of VAT using the DNeasy Blood 
& Tissue kit (QIAGEN, Mississauga, Ontario, Canada), 
as recommended by the manufacturer. Bisulfite conver-
sion was conducted on 1  µg of DNA, and quantitative 
DNA methylation analysis was carried out at the McGill 
University and Génome Québec Innovation Centre 
(Montreal, Canada), using the Infinium HumanMeth-
ylation450 BeadChip (Illumina Inc., San Diego, CA). The 
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BeadChip interrogates more than 485,000 methylation 
sites at single-nucleotide resolution. Methylation data 
was visualized and analyzed using the GenomeStudio 
software version 2011.1 (Illumina Inc.) and the methyla-
tion module. Methylation levels (β values) were estimated 
as the ratio of signal intensity of the methylated alleles to 
the sum of methylated and unmethylated intensity sig-
nals of the alleles. The ratio of methylation intensities for 
each sample was obtained from multiple measurements 
of the same probe sequence (a median of 14 beads ran-
domly distributed across the array), providing a reliable 
and consistent internal control probe set [21, 22]. Data 
correction (background subtraction and normalization) 
was applied using internal control probe pairs. CpG sites 
with a detection P > 0.05 were removed from analysis. β 
values of CpG sites located within the TOMM20 locus 
(~2 kb upstream and downstream) were extracted using 
the GenomeStudio methylation module.
SNP genotyping
The identification of TOMM20 tag SNPs (tSNPs) for 
further genotyping was carried out using the tag-
ger selection algorithm of the Haploview software [23, 
24]. Selection of tSNPs within the TOMM20 locus 
(—1:235272658-235292256, GRCh37/hg19) and flank-
ing regions (~2 kb downstream and upstream) was per-
formed based on linkage disequilibrium (LD r2 < 0.8) and 
minor allele frequency (MAF >5 %), considering the CEU 
panel (Utah residents with Northern and Western Euro-
pean ancestry) of the latest release of the 1000 genomes 
project (phase 3) [25]. Genotyping was performed on 
genomic DNA extracted from the blood buffy coat using 
the GenElute Blood Genomic DNA kit (Sigma, St. Louis, 
MO, USA). Selected tSNPs were genotyped in the entire 
population of 1720 severely obese individuals using vali-
dated primers and TaqMan probes (Applied Biosystems). 
Genotypes were determined using 7500 Fast Real-Time 
PCR System (Applied Biosystems) and analyzed using a 
high-throughput array technology QuantStudio 12K Flex 
system, coupled with Taqman OpenArray technology 
(Life Technologies).
Statistical analyses
Metabolic and anthropometric differences between MS+ 
and MS– subjects were computed using unpaired Stu-
dent’s t test. meQTL associations were tested in VAT 
samples using the analysis of variance (general linear 
model, type III sum of squares) with age, sex and BMI 
included in the model. Pairwise comparisons among 
genotype groups were performed using least square 
means (LS-means) when a significant meQTL was identi-
fied. Statistical significance was defined as P ≤ 0.05 and 
Benjamini-Hochberg multiple testing correction (false 
discovery rate [FDR]-corrected P  ≤  0.05) was applied. 
Metabolic traits were transformed to dichotomous 
variables and coded as low- and high-risk for a MS-
related trait, according to NCEP-ATPIII criteria [Fast-
ing glucose ≥5.6 mmol/L, total-C ≥6.2 mmol/L, LDL-C 
≥4.1  mmol/L, HDL-C ≤1.03 (males) or ≤1.39  mmol/L 
(females), TG ≥1.69  mmol/L, Total-C/HDL-C ≥5, TAS 
≥130 mmHg, TAD ≥85 mmHg]. Individuals taking any 
medication to treat one of these metabolic conditions 
were considered to meet the criteria for such condition, 
as previously described [26]. The Cochran–Armitage 
exact test for trend (two-sided) was used to compare the 
proportion of men and women belonging to the low- and 
high-risk groups for a given MS-related trait. Associa-
tions with metabolic risk groups were tested by logistic 
regression under a dominant model of inheritance (com-
mon homozygotes vs. heterozygotes plus rare homozy-
gotes), adjusting the genotype effect for age, sex and 
BMI. The odds ratios (OR) and Wald’s confidence inter-
vals (CI) were computed. Diplotype-based logistic mod-
els adjusted for age, sex and BMI were fitted and specific 
diplotype effects by sex were computed. Statistical signif-
icance was defined as P ≤ 0.05. Statistical analyses were 
performed using SAS software version 9.3 (SAS Institute, 
NC, USA).
Bioinformatic analyses
Haploview software [23] was used to verify HWE and 
calculate MAF for each SNP. SNP imputation was per-
formed with PLINK v1.07 [27] using the CEU panel of the 
1000 Genomes Project (Phase 3) as the reference popula-
tion. Haplotype reconstruction and individual diplotype 
assignments were inferred from genotype data using 
PHASE software version 2.1.1 [28] with default param-
eters. The predicted transcription factor (TF) binding 
affinities were analyzed using TRAP [29]. The sequence 
overlapping a differentially methylated CpG site (10  bp 
upstream and downstream) was used as input sequence. 
The Transfac vertebrates 2010.1 database was used as TF 
matrix and human promoter sequences were introduced 
as background model to compare affinities.
Results
Characteristics of subjects
From a total of 1720 severely obese subjects, 1717 were 
successfully designated either as MS+ (1402) or MS− 
(315). As shown in Table 1, MS+ patients showed a signif-
icant elevation of fasting glucose, waist girth and systolic 
blood pressure (SBP), as compared to MS− group. All 
plasma lipid measurements also showed significant dif-
ferences between MS+ and MS− groups, with TG and 
total-C/HDL-C showing a significant elevation in MS+ 
subjects, and with total-C, LDL-C and HDL-C showing 
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decreased levels in MS+ as compared to the MS− group. 
Similar significant differences were also found between 
MS+ and MS− subjects in the sub-population of 48 indi-
viduals used for methylation analysis. Concretely, a sig-
nificant increase in fasting glucose, total-C, TG, total-C/
HDL-C, SBP and DBP were found in the MS+ group, as 
well as a significant decrease in HDL-C levels (Table 1). 
On the other hand, Cochran–Armitage tests showed that 
men were more prone to MS than women [OR =  1.65, 
95  % CI (1.27−1.84)]. In addition, a significantly higher 
proportion of men, as compared to women, also encom-
passed in the high-risk group for every MS-related trait 
tested, except for HDL-C (Data not shown).
Methylation profile of TOMM20 locus
The CpG methylation profile of TOMM20 locus showed 
a total of 20 CpG sites located within a CpG island (CGI) 
and CGI flanking regions (Fig. 1). Mean methylation lev-
els of these regions showed the expected distribution of 
methylation, with hypermethylated sites mainly located 
outside the CGI in both upstream and downstream CGI 
flanking regions (Mean β values  =  0.5 and 0.7, respec-
tively) and with CGI showing a characteristic hypometh-
ylation (Mean β value = 0.1). We found that the CpG site 
cg16490124, previously reported as differentially methyl-
ated between MS+ and MS− [13], was located within the 
CGI and showed a large methylation heterogeneity, rang-
ing from ~2 to ~97 % (Fig. 1).
SNP genotyping and imputation
SNP tagging selection led to the identification of 
five tSNPs located downstream (rs4567344/A  >  G, 
rs7411516/G > A), at the 3′-UTR region (rs11301/T > C), 
at intron 4 (rs4551650/G  >  A) and upstream the 
TOMM20 locus (rs7513381/A  >  G) (Fig.  1). This 
approach allowed us to cover 100  % of the sequence-
derived genetic variability at the TOMM20 locus. 
Moreover, since cg16490124 showed partial methyla-
tion, typically exhibited by CpG sites overlapping with a 
SNP [12], we proceeded to the imputation of previously 
captured SNPs during tagging selection, in order to find 
such a CpG-SNP [30]. SNP imputation led to the iden-
tification of a SNP (rs17523127/G > C) overlapping with 
cg16490124, with an imputation call rate of 99  % and a 
confidence threshold of 0.8. LD analysis showed high 
degree of LD (r2  =  0.87) between rs4551650 and the 
imputed SNP rs17523127. A certain degree of LD was 
also observed between rs11301 and rs4567344 (r2 = 0.56) 
(Fig. 1). All the genotyped and imputed SNPs showed a 
MAF >5  % and were in Hardy–Weinberg equilibrium 
(HWE) (Additional file 1: Table S1).
Identification of TOMM20 meQTL
Association testing for meQTL identification was per-
formed with genotyped and imputed SNPs in the 
subset of 48 severely obese subjects. As expected, 
rs17523127 was identified as a statistically significant 
Table 1 Characteristics of subjects
Metabolic and anthropometric values in the study population (n = 1720) and in the methylation sub‑population (n = 48) of severely obese subjects with and without 
MS (MS+ and MS−, respectively). Data is expressed as mean ±SD. Asterisks stand for significant differences between MS+ vs. MS− subjects using unpaired Student’s t 
test (*** P ≤ 0.0001, ** P ≤ 0.01, * P ≤ 0.05, ns: not significant)
BMI body mass index, Total‑C total cholesterol, LDL‑C low‑density lipoprotein cholesterol, HDL‑C high‑density lipoprotein cholesterol, TG triglycerides, SBP systolic 
blood pressure, DBP diastolic blood pressure
Study population Methylation sub-population
MS+ MS− MS+ MS−
Number of subjects 1402 315 25 23
Age (years) 43.9 ± 10.5 38.7 ± 9.8*** 33.9 ± 9.4 32.0 ± 7.9
BMI (kg/m2) 51.8 ± 8.5 51.3 ± 8.7 52.6 ± 12.7 52.3 ± 8.4
Waist girth (cm) 141.5 ± 17.2 135.6 ± 18.5*** 149.4 ± 24.8 143.3 ± 17.1
Fasting glucose (mmol/L) 6.85 ± 2.43 5.11 ± 0.98*** 6.61 ± 2.79 4.95 ± 0.46**
Lipid profile (mmol/L)
 Total‑C 4.67 ± 0.96 4.80 ± 0.82* 4.93 ± 0.75 4.47 ± 0.87**
 LDL‑C 2.65 ± 0.83 2.79 ± 0.75** 2.89 ± 0.65 2.68 ± 0.77
 HDL‑C 1.18 ± 0.32 1.49 ± 0.37*** 0.96 ± 0.19 1.28 ± 0.17***
 TG 1.97 ± 1.12 1.17 ± 0.37*** 2.40 ± 1.30 1.12 ± 0.45***
 Total‑C/HDL‑C 4.18 ± 1.34 3.33 ± 0.74*** 5.32 ± 1.49 3.51 ± 0.56***
Blood pressure (mm Hg)
 SBP 139 ± 16.7 134.7 ± 15.7*** 145 ± 19.8 130.8 ± 13.2**
 DBP 84 ± 11.3 83.0 ± 10.3 89 ± 12.0 78.0 ± 9.7**
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meQTL for cg16490124 (P  =  3.5  ×  10−15). Given the 
strong LD between each other, rs4551650 (16.1 kb from 
CpG site) also showed a significant association with 
cg16490124 (P  =  3.5  ×  10−15) (Fig.  2). Methylation 
levels at cg16490124 were significantly higher in het-
erozygotes and rare homozygotes of both meQTLs than 
common homozygotes (Fig.  2). On the other hand, two 
other SNPs also showed a significant but weaker asso-
ciation with methylation levels of this CpG site, rs11301 
(P  =  5.9  ×  10−3) and rs4567344 (P  =  4.9  ×  10−2). 
Interestingly, both SNPs showed the opposite rela-
tionship with cg16490124 methylation levels, i.e. rare 
allele carriers of rs4567344 and rs11301 (located 21.6 
and 19.2  kb from CpG site, respectively) showed a sig-
nificant decrease in methylation levels as compared to 
individuals carrying the common homozygote (Fig.  2). 
After Benjamini–Hochberg multiple testing correction, 
only rs17523127 (FDR-corrected P  =  4.1  ×  10−13) and 
rs4551650 (FDR-corrected P =  4.1 ×  10−13) held a sig-
nificant association with cg16490124 methylation levels.
Association between TOMM20 meQTLs and MS-related 
metabolic traits
Logistic regression analysis revealed significant associa-
tions between meQTLs and MS-related lipid traits. First, 
meQTLs whose rare allele had shown increased methyla-
tion levels, rs4551650 (G > A) and rs17523127 (G > C), 
were associated with total-C under a dominant model 
of inheritance. In particular, the proportion of rare allele 
carriers observed in the high total-C group was signifi-
cantly lower than that of common homozygotes of both 
rs4551650 (χ2 = 4.8, P = 0.03) [OR = 0.78, 95 % CI (0.63–
0.97)] and rs17523127 (χ2 =  4.6, P =  0.03) [OR =  0.78, 
95 % CI (0.63–0.98)], thus suggesting a protective effect 
of these meQTLs for high total-C levels. This association 
was lost when analyzed separately in men and women 
(Data not shown). On the other hand, meQTLs showing 
a decrease in cg16490124 methylation levels, rs4567344 
(A  >  G) and rs11301 (T  >  C), were significantly associ-
ated with plasma TG levels. Concretely, individuals 




































































Fig. 1 Methylation profile and linkage disequilibrium (LD) map 
within the TOMM20 locus. The upper part of the figure shows mean 
methylation levels of the 20 CpG (CpG island—grey bars; upstream 
and downstream regions—black bars) identified within TOMM20 
locus in visceral adipose tissue samples (n = 48). Methylation levels 
shown as average β values ranging from 0 (unmethylated) to 1 (com‑
pletely methylated). The lower part shows the LD map of genotyped 
and imputed SNPs within TOMM20 locus in the study population 
(n = 1720), considering the CEU panel (Utah residents with Northern 
and Western European ancestry) of the latest release of the 1000 
Genomes Project (Phase 3). LD r2 values (%) are shown in boxes. The 
imputed SNP is marked with an asterisk
Fig. 2 Mean degree of cg10738648 methylation for each meQTL 
identified in visceral adipose tissue samples. CpG methylation levels 
are shown as average β values ranging from 0 (unmethylated) to 1 
(completely methylated). Values presented (mean ± SE) and P values 
were obtained by general linear models (type III sum of squares) 
adjusted for the effect of age, sex and BMI (n = 48). Pairwise compari‑
sons among genotype groups were performed using least square 
means (LS‑means) and asterisks represent significant differences vs. 
common homozygotes. ***P ≤ 0.0001, **P ≤ 0.01, *P ≤ 0.05
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[OR  =  1.32, 95  % CI (1.08–1.62)] and rs4567344 
(χ2  =  6.4, P  =  0.01) [OR  =  1.30, 95  % CI (1.06–1.59)] 
were significantly more represented in the high plasma 
TG group. This association was slightly higher in men for 
both meQTLs, rs11301 (χ2 = 4.6, P = 0.03) [OR = 1.51, 
95 % CI (1.04–2.19)] and rs4567344 (χ2 = 6.4, P = 0.01) 
[OR = 1.64, 95 % CI (1.12–2.40)], but it was completely 
lost in women (Data not shown) when analyzed sepa-
rately. In view that opposite associations found between 
meQTLs and cg16490124 methylation levels mirrored 
those observed with phenotype traits, we performed a 
diplotype-based analysis to unveil the whole effect of the 
simultaneous presence of these meQTLs.
Diplotype-based phenotype associations
Haplotype reconstruction with significant meQTLs 
(rs4567344, rs11301, rs4551650, rs17523127) led to the 
identification of four major haplotypes, scattered into 
ten different diplotypes (Table  2). Carriers of the H2/
H2 diplotypes were excluded for association analysis 
because of low frequency (0.7  %). The H3/H3 diplotype 
was considered as the reference group carrying common 
homozygotes of the four meQTLs. Only those diplo-
types composed of common alleles of rs4551650 (G) and 
rs17523127 (G) and rare alleles of rs4567344 (G) and 
rs11301 (C), namely H1/H2 (5.1 %) and H1/H3 (18.0 %), 
showed significant associations with MS-related traits. 
In particular, H1/H2 diplotype showed the most signifi-
cant associations with total-C, LDL-C and TG high-sus-
ceptibility groups in the entire population (Table  3). In 
view that men and women had shown a significantly dif-
ferent risk for MS per se and for most of the MS-related 
metabolic traits, diplotype-based analysis was performed 
independently in both sexes. The results obtained were 
remarkable in the men sub-population, where an overall 
OR increase in both H1/H2 and H1/H3 diplotypes was 
observed for total-C, LDL-C and TG high-susceptibil-
ity groups, as compared to those obtained in the entire 
population. By contrast, no significant differences were 
observed in the women sub-population (Table 3).
Diplotype-based meQTL associations and impact on TF 
binding affinity
Diplotype-based logistic models suggested that asso-
ciations found between diplotypes H1/H2 and H1/
H3 with MS-related lipid traits could be due to the 
absence of methylation at cg16490124. meQTL asso-
ciation test revealed that H1/H2, the diplotype show-
ing the strongest associations with total-C, LDL-C and 
TG levels, exhibited a nearly absence of methylation at 
cg16490124 (Fig. 3a). On the other hand, H1/H3 showed 
partial methylation and, as expected, those diplotypes 
carrying rare homozygotes of both rs4551650 (AA) 
and rs17523127 (CC) showed higher methylation lev-
els (Fig.  3a). Since the association between meQTL and 
lipid profile appeared to be modulated by methylation 
levels at cg16490124, located within the promoter region 
of TOMM20, we investigated whether this CpG site 
was encompassed by TF binding sites (TFBS). On the 
inclusion of a flanking sequence of 10 bp upstream and 
downstream the CpG site, TRAP results revealed that 
cg16490124 encompassed several putative TFBS, accord-
ing to Transfac matrix similarities (Data not shown). 
Interestingly, the most significantly overrepresented TF 
Table 2 Haplotype and diplotype patterns and frequencies for TOMM20
Numbers 1 and 0 indicate common and rare allele, respectively
a The reference diplotype
Haplotypes (H) rs4567344 (A > G) rs11301 (T > C) rs4551650 (G > A) rs17523127 (G > C) Frequency (%)
H1 0 0 1 1 25.3
H2 1 0 1 1 10.1
H3 1 1 1 1 35.1
H4 1 1 0 0 29.5
Diplotypes
 H1/H1 0/0 0/0 1/1 1/1 6.6
 H1/H2 0/1 0/0 1/1 1/1 5.1
 H1/H3 0/1 0/1 1/1 1/1 18.0
 H1/H4 0/1 0/1 1/0 1/0 14.4
 H2/H2 1/1 0/0 1/1 1/1 0.7
 H2/H3 1/1 0/1 1/1 1/1 7.2
 H2/H4 1/1 0/1 1/0 1/0 6.3
 H3/H3a 1/1 1/1 1/1 1/1 12.0
 H3/H4 1/1 1/1 1/0 1/0 21.2
 H4/H4 1/1 1/1 0/0 0/0 8.6
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binding matrices, that remained significant after mul-
tiple testing correction, corresponded to Early growth 
response proteins 1, 2 and 3 [Egr1 (P  =  6.3  ×  10−05), 
Egr2 (P = 1.7 × 10−07) and Egr3 (P = 3.6 × 10−06)], three 
members of the Egr family of zinc finger TFs. Position-
specific scoring matrices showed identical consensus 
sequence at the TFBS core region of the three Egr (Addi-
tional file  1: Figure S1). Using the ENCODE ChIP-Seq 
data in UCSC genome browser, we discovered a peak of 
Egr1-binding at TOMM20 promoter region, overlapping 
with cg16490124 (Fig. 3b). Finally, the comparison of the 
input sequence used for TRAP prediction with Egr1-
binding sites, led to the identification of the CpG-SNP 
rs17523127 as being located within the TFBS core region 
(Fig. 3c).
Discussion
In the present work, we aimed to analyze whether poten-
tial meQTLs located within the TOMM20 locus were 
associated with MS-related metabolic traits. In this 
Table 3 Diplotype- and sex-based logistic regression analysis
Diplotype‑based logistic regression analyses were fitted including sex, age and BMI as confounding factors in the entire population (n = 1720), and including age 
and BMI when men and women were analyzed separately (n = 537 and n = 1183, respectively). The H3/H3 diplotype was set as the reference group for comparison 
purposes since it carries wild type alleles of the four meQTLs tested. Significant Wald‑tests are shown in italic face (P ≤ 0.05)
OR odds ratio, CI 95 % Wald’s confidence intervals, Total‑C total cholesterol, LDL‑C low‑density lipoprotein cholesterol, TG triglycerides
All Men Women
Wald χ2 (P value) OR (95 % CI) Wald χ2 (P value) OR (95 % CI) Wald χ2 (P value) OR (95 % CI)
Total‑C H1/H2 5.9 (0.01) 2.03 (1.59–3.59) 4.7 (0.03) 3.00 (1.11–8.06) 1.7 (0.19) 1.60 (0.79–3–24)
H1/H3 1.5 (0.23) 1.29 (0.85–1.96) 4.3 (0.04) 2.10 (1.04–4.25) 0.0 (0.99) 1.00 (0.60–1.68)
LDL–C H1/H2 4.6 (0.03) 1.86 (1.06–3.27) 6.2 (0.01) 3.54 (1.31–9.58) 0.6 (0.45) 1.31 (0.65–2.62)
H1/H3 1.9 (0.17) 1.34 (0.89–2.02) 7.1 (0.008) 2.64 (1.29–5.41) 0.1 (0.80) 0.94 (0.57–1.55)
TG H1/H2 8.1 (0.004) 2.19 (1.28–3.74) 9.8 (0.002) 7.02 (2.07–13.76) 1.4 (0.24) 1.46 (0.78–272)
H1/H3 3.3 (0.03) 1.53 (1.03–2.26) 6.1 (0.01) 2.43 (1.20–4.93) 0.3 (0.57) 1.14 (0.73–1.78)
a b
c
Fig. 3 Mean methylation levels of cg10738648 for each diplotype and a schematic representation of Erg1‑binding sites. a Mean degree of 
cg16490124 methylation levels for diplotypes in visceral adipose tissue samples. CpG methylation levels are shown as average β values ranging 
from 0 (unmethylated) to 1 (completely methylated). Values presented (mean ±SE) and P values were obtained by general linear models (type 
III sum of squares) adjusted for the effect of age, sex and BMI (n = 48). Asterisks represent significant differences vs. H3/H3 (reference diplotype). 
***P ≤ 0.0001. b Schematic representation of the TOMM20 promoter region showing Erg1‑binding sites (horizontal red bar), CpG island (horizontal 
green bar), cg16490124 and rs175231127, obtained from ENCODE data in the UCSC genome browser. c Sequence logo is the graphical representa‑
tion of the Egr1 position‑specific scoring matrix (PSSM) identified by TRAP and obtained from the Transfac database (ID: M00243). Sequence logo 
shows the base preference, sized and sorted relative to their occurrence in the PSSM. The location of the CpG‑SNP rs175231127 (G > C) within the 
Egr1‑binding site is marked with an arrow
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regard, recent studies focused on the interplay between 
CpG methylation levels and the underlying genetic 
sequence, as carried out here, have emerged as suit-
able tools to detect disease biomarkers [34–36]. Overall, 
the main findings of this study reinforce the assump-
tion that the link between epigenetics and the underly-
ing genetic sequence may be further reflected in the 
phenotype, as previously highlighted [33]. In particu-
lar, significant meQTLs identified within the TOMM20 
locus showed relevant associations with MS-related lipid 
traits, specifically with higher susceptibility of increased 
total-C, LDL-C and TG levels. Interestingly, two of the 
meQTLs identified within the TOMM20 locus, rs11301 
and rs4567344, whose rare alleles showed a decrease in 
methylation levels of cg16490124, were both signifi-
cantly associated with increased risk of high TG levels. 
By contrast, individuals carrying rare alleles of rs4551650 
and rs17523127 showed increased methylation levels 
at the same CpG site and a protective effect on total-C 
levels. Since the impact of meQTL on phenotype traits 
are eventually due to an additive effect of two or more 
genetic variants, leading to a sum of small effects [31], we 
hypothesized that relatively weak associations obtained 
with independent genotypes could be largely explained 
by a diplotype effect. As such, H1/H2 and H1/H3 diplo-
types were more strongly associated with increased 
susceptibility to exhibit high TG levels than the single 
genotypes (rs11301 and rs4567344), suggesting a poten-
tial additive effect of both meQTLs. Moreover, diplotype 
analyses provide a more accurate and powerful esti-
mation of the genetic effects on multifactorial-disease 
traits, and might unveil a larger overall effect if antago-
nistic genetic interactions are present [32]. Intriguingly, 
we provide evidence that diplotypes composed of rare 
allele carriers from rs11301 and rs4567344 and common 
homozygotes from rs4551650 and rs17523127 not only 
abolished the protective effect shown independently by 
rs4551650 and rs17523127 on total-C levels, but they 
were in fact significantly associated with a high risk of 
exhibiting elevated total-C and LDL-C levels, thus sug-
gesting a CpG methylation-mediated effect. In this sense, 
non-coding SNPs as those tested here are supposed 
to have an impact on the phenotype through indirect 
means, e.g. altering methylation levels (meQTL) or TFBS 
[33], which does not necessarily imply a linear correlation 
with a quantitative gene expression change (eQTL) or a 
phenotype trait [34], but an additive association model. 
Then, since polymorphisms tested in complex diseases 
rarely account for a large proportion of the variance, it 
was thus unlikely to obtain high significance levels unless 
a very impressive cohort was used. In this context, cor-
rections for multiple testing would lead to too stringent 
significance threshold and may result in false negatives in 
such a discovery study. Instead, the potential associations 
with phenotype traits were assessed by logistic regres-
sion adjusted for age, sex and BMI to avoid the occur-
rence of casual relationships, and subsequently tested by 
means of a diplotype-based logistic regression, in order 
to detect stronger associations supporting previous 
results. Indeed, as previously mentioned, hidden asso-
ciations revealed by diplotype-based analysis suggested 
that methylation levels at cg16490124 could be modulat-
ing the impact of SNPs on the phenotype. In this sense, 
one of the functional outcomes derived from altered gene 
methylation profile at promoter regions is usually the 
alteration of TFBS.
The transcriptomic study in which TOMM20 showed a 
significantly overexpression in subjects with MS was per-
formed in a relatively small cohort of 14 severely obese 
men [15], which made not possible to conduct associa-
tion studies or correlation analysis with methylation lev-
els with sufficient statistical power. Nonetheless, the goal 
of this study was not specifically to find out this func-
tional outcome, but to focus on the potential association 
between TOMM20 SNPs and obesity-associated meta-
bolic traits. In any case, we did study the potential effect 
of the differentially methylated CpG site cg16490124 
on TOMM20 transcription regulation by analyzing its 
impact at TFBS. It is worth noting that cg16490124 is 
located within a typically hypomethylated CpG island 
which mainly encompasses the binding sites for nuclear 
respiratory factor 2 (Nrf-2), previously described as 
a required TF for TOMM20 gene expression [35, 36]. 
Intriguingly, when the CpG surrounding sequence was 
examined for TF binding affinities, Nrf-2 binding site was 
not found among the most significant motifs. By contrast, 
highly significant affinities were found for Egr1-, Egr2- 
and Egr3-binding sites. Egr1 and Egr2 proteins are closely 
related to adipocyte differentiation, with Egr2 pro-adipo-
genic effects being potentiated by Egr1 knockdown [37]. 
Moreover, a strong correlation between Egr1 expression 
levels with dietary-induced obesity has been found in 
both mice and humans [38]. In this context, Egr-1 null 
mice would be protected against obesity-related compli-
cations, such as elevated circulating TG levels, by a mech-
anism possibly mediated by FOXC2, increasing energy 
expenditure and altering mitochondrial function [38]. 
Since TOMM20 has a key role in maintaining mitochon-
drial biogenesis and function [36, 39, 40], the significant 
affinities found between Egr proteins with the underlying 
sequence of cg16490124 point to a potential new path-
way leading to adipocyte dysfunction. Thus, it is conceiv-
able that increased methylation levels of cg16490124, 
located within TOMM20 promoter and encompassed by 
Egr-binding sites, results in decreased Egr1 binding, thus 
leading to a protective effect as that observed between 
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rs4551650 and rs17523127 with total-C levels. There-
fore, a potential alteration on these TFBS could account 
for the observed alterations of MS-related lipid features 
in severely obese patients. Although we do acknowledge 
that in silico studies do not represent a mechanistic cause 
of the disease and need to be validated by functional 
studies, we consider that these results pointing to Egr 
proteins agree with TOMM20 physiological function and 
suggest a potential role of this gene in the development 
of dysfunctional adipocytes. These results thus represent 
a starting point for further functional studies focused on 
assessing the actual impact of meQTLs using functional 
genomics approaches, including transfection assays or 
measurements of gene expression in cells derived from 
carriers/non-carriers of the above mentioned meQTLs.
Finally, a stronger risk of high total-C, LDL-C and 
TG levels was found in men carrying H1/H2 and H1/
H3 diplotypes, as compared to women. Although it has 
been well established that energy expenditure and lipid 
homeostasis differ between men and women [41], the 
underlying mechanisms leading to these sex differences 
remain to be elucidated. Herein, we have noted that men 
were more prone than women to MS and to most of MS-
related complications. Regarding MS-related lipid traits, 
the impact of meQTLs on the phenotype mirrored these 
differences, thus providing a clue to understand the dif-
ferent susceptibility to MS between men and women, as 
previously suggested by others [42–44].
Conclusions
This study demonstrates that TOMM20 SNPs associ-
ated with MS-related lipid alterations are meQTLs thus 
potentially exerting their action in a CpG methylation-
dependent way. The strength of the diplotype-based asso-
ciations with total-C, LDL-C and TG levels may denote 
a novel meQTL additive action, an effect worthy of fur-
ther analysis in larger methylation cohorts to broaden 
the knowledge of interactions between gene variation 
and CpG methylation on the susceptibility to MS-related 
complications.
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